CAR T-cells Targeting CD20-positive Non-Hodgkin’s Lymphoma Safe and Effective, Long-term Study Shows – Lymphoma News Today
Lymphoma News Today |
CAR T-cells Targeting CD20-positive Non-Hodgkin’s Lymphoma Safe and Effective, Long-term Study Shows
Lymphoma News Today A long-term follow-up study of immunotherapy with CAR T-cells in patients with B-cell non-Hodgkin’s lymphoma with CD20-carrying B-cells show the approach is similar in effectiveness and safety to the more common CAR T-cell therapy. The study, published … |
Forbes |
Here Come More Gene Therapies — And More Pricing Debates
Forbes The Food and Drug Administration approved the first gene therapy in August and is considering another for approval soon. Designed as one-time treatments, they don’t come cheap, and that’s raising concerns among health care payers. (AP Photo/Andrew … Gene Therapy for Blindness Appears Initially Effective, Says US FDAScientific American The FDA is Considering a Landmark Approval of Gene Therapy to …Gizmodo With AdComm meeting looming, FDA shares concerns about Spark’s lead gene therapyFierceBiotech ABC News –Business Insider –WebMD all 63 news articles » |
News-Medical.net |
Agilent collaborate with Doulix to promote SureVector cloning kits
News-Medical.net Double Helix Technologies (Doulix) announced a collaboration with Agilent Technologies Inc. to promote Agilent’s SureVector next-generation cloning kits through Doulix’s web platform. Through this partnership, synthetic biologists will be able to … |